Adding steroid drug to MS treatment may reduce disease activity

Apr 30, 2009

Using a steroid drug for multiple sclerosis (MS) in addition to an MS drug may reduce the amount of disease activity more than using the MS drug alone, according to a study that will be presented as part of the Late-breaking Science Program at the American Academy of Neurology's 61st Annual Meeting in Seattle, April 25 - May 2, 2009.

For the study, people with MS received the steroid drug methylprednisolone in monthly "pulses," or three doses over three days, in addition to regular weekly treatment with the drug interferon beta-1a. The steroid drug has typically been used only to treat acute MS attacks, not as an ongoing treatment.

The study involved 341 people with relapsing-remitting MS. Half of the participants received both drugs; half received only the interferon drug plus a placebo. The participants were seen every three months during the three-year study for evaluation.

The participants had the disease for an average of three years and had not yet received a disease-modifying drug such as interferon.

Those who received both drugs had 38 percent fewer relapses, or times when the disease is active, than those receiving only the interferon drug. They also improved slightly on a test of MS disability, while the scores for the group decreased slightly.

At the beginning of the study and again after three years, the researchers measured the size of lesions in the brain that are a sign of disease activity. For those receiving both drugs, the lesions stayed the same size or shrunk, while the size of the lesions grew for those taking only interferon.

"These results indicate that these two drugs may have a synergy when taken together and provide a more beneficial effect on the disease activity," said study author Mads Ravnborg, MD, of the Danish Research Center at Copenhagen University Hospital in Denmark. "This is a promising finding, as the benefit from interferon is only moderate and not everyone responds fully to the treatment, so anything we can do to boost those results is positive."

Source: American Academy of Neurology (news : web)

Explore further: Pre-op MRI predicts outcome of cervical spondylotic myelopathy

add to favorites email to friend print save as pdf

Related Stories

If MRI shows signs of MS, will the disease develop?

Dec 10, 2008

With more and more people having brain MRIs for various reasons, doctors are finding people whose scans show signs of multiple sclerosis (MS) even though they have no symptoms of the disease. A new study published in the ...

Young smokers increase risk for multiple sclerosis

Feb 23, 2009

People who start smoking before age 17 may increase their risk for developing multiple sclerosis (MS), according to a study released today that will be presented at the American Academy of Neurology's 61st Annual Meeting ...

New hope for multiple sclerosis sufferers

Oct 22, 2008

A drug which was developed in Cambridge and initially designed to treat a form of leukaemia has also proven effective against combating the debilitating neurological disease multiple sclerosis (MS).

Recommended for you

Sexually transmitted HPV declines in US teens

4 hours ago

The number of US girls with the sexually transmitted disease HPV has dropped by about half even though relatively few youths are getting the vaccine, research showed on Wednesday.

User comments : 0

More news stories

The broken symphony of swinging metronomes

An experiment with 30 metronomes reveals chimera states which combine aspects of synchrony and of disorder. Researchers had been looking for such states for ten years.

Wooden beam could be detached part of shipwreck

A wooden beam that has long been the focus of the search for a 17th century shipwreck in northern Lake Michigan was not attached to a buried vessel as searchers had suspected, but still may have come from the elusive Griffin ...

Microsoft mulled buying Nokia unit

Microsoft was in talks to boost its position in the mobile phone market by buying the devices business from Nokia but failed to seal a deal, the Wall Street Journal reported Wednesday.